LiDCO Group Plc Latest monitor launched in China (2267S)
05 Novembre 2019 - 8:00AM
UK Regulatory
TIDMLID
RNS Number : 2267S
LiDCO Group Plc
05 November 2019
LiDCO Group Plc
("LiDCO" or the "Company")
Latest monitor launched in China
LiDCOrapid(v3) monitor launches in the second largest healthcare
market in the world
LiDCO (AIM: LID), the hemodynamic monitoring company, announces
that the LiDCOrapid(v3) monitor, LiDCO's latest cardiac output
monitor with non-invasive technology has been launched in China at
the 27(th) Annual Meeting of the Chinese Society of Anesthesiology
(CSA2019), which was held in Hangzhou.
This follows the Company receiving Chinese Food and Drug
Administration ("CFDA") approval in July 2019. The Company's
hemodynamic LiDCOrapid(v3) monitor product will be sold via LiDCO's
distribution partner, Beijing Gloryway Medical Co., Ltd
("Gloryway"). Gloryway is a leading medical device sales group
specialising in anaesthesia and patient monitoring with a direct
commercial presence in China. Uniquely LiDCO will be the only
western supplier of hemodynamic monitoring solutions that is
manufacturing its product locally in China. This could be a key
differentiator as the vast majority of the 22,000 hospitals in
China can only procure domestically manufactured products. China is
the second largest healthcare market in the world with a five-year
compound annual growth rate by value of 17% compared with 4% in the
United States(1) .
Over the last few years an increasing number of clinical studies
originating from China have been published, reinforcing the
positive impacts of hemodynamic monitoring proven in studies
elsewhere in the world. This is helping to drive adoption of
hemodynamic monitoring technologies in China, which represents a
substantial opportunity for the Company.
The Board anticipates that this launch will be a key contributor
to the Company's future international sales growth.
Commenting, Matt Sassone, Chief Executive Officer of LiDCO,
said: "We have worked with our distribution partner, Gloryway, for
a number of years. This launch is strategically important for LiDCO
and we believe that this could lead to significant sales growth in
this rapidly growing market for hemodynamic monitoring."
(1) - Major healthcare markets defined as top five global
markets by the World Health Organization. 6/30/2018
For further information, please contact:
LiDCO Group Plc www.lidco.com
Matt Sassone (CEO) Tel: +44 (0)20 7749 1500
Tim Hall (CFO)
finnCap Tel: +44 (0)20 7600 1658
Geoff Nash / Hannah Boros (Corporate
Finance)
Andrew Burdis (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or lidco@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive
hemodynamic equipment to hospitals used to monitor the amount of
blood flowing around the body and ensure that vital organs are
adequately oxygenated. LiDCO's products facilitate the application
of hemodynamic optimisation protocols for high risk patients in
both critical care units and in the operating theatre.
Increasingly clinical studies have shown that the optimisation
of patients' hemodynamic status in high risk patients produces
better outcomes and reduced hospital stay. LiDCO's computer-based
technology, developed originally at St Thomas' Hospital in London,
has been shown to significantly reduce morbidity and complications,
length of stay and overall costs associated with major surgery.
Key Products:
LiDCOunity: a hemodynamic monitor that combines the full suite
of LiDCO technology (non-invasive, minimally invasive and
calibrated technologies) into one platform. Designed to have the
flexibility to adapt to a patient's changing acuity, the product
enables clinicians to seamlessly transition between non-invasive,
minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus: a computer-based platform monitor used in the
Intensive Care Unit for real-time continuous display of hemodynamic
parameters including cardiac output, oxygen delivery and
fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid: a cardiac output monitor designed specifically for
use in the operating theatre for fluid and drug management. The
monitor enables anaesthetists to receive accurate and immediate
feedback on the patient's fluid and hemodynamic status - a key
measure of overall well-being before, during and after surgery. The
LiDCOrapid provides:
-- early and rapid warning of hemodynamic change to aid choice
of therapeutic route: fluid or drug
-- quantification of hemodynamic response guidance on effective
delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid
monitor to co-display Medtronic's level of consciousness parameter
('BIS(TM') )* and add the convenience of CNSystem's continuous
non-invasive blood pressure monitoring ('CNAP')**. This addresses a
growing requirement for non-invasive monitoring solutions that are
more comprehensive and can effectively replace multiple single
parameter monitors.
LiDCOview: an easy-to-use graphical display of historical
LiDCOplus and LiDCOrapid hemodynamic data.
*BIS(TM) and Bispectral Index are trademarks of Medtronic
registered in the US and foreign countries.
**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or
smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through
a network of specialty critical care and anaesthesia distributors
in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on
AIM.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKMMGMNDMGLZM
(END) Dow Jones Newswires
November 05, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Lidco (LSE:LID)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Lidco (LSE:LID)
Storico
Da Apr 2023 a Apr 2024